Insulin Exclusivity: How Big Will The Fight Be?
Executive Summary
As FDA gears up to turn some NDAs into BLAs, insulins may have the most to lose – or gain, if the agency changes its approach.
You may also be interested in...
Sanofi's Admelog, a Humalog Follow-On, Approved In US As 'Black Hole' For Insulins Looms
Short-acting insulin approved under 505(b)(2) pathway appears poised to receive three years of Hatch-Waxman exclusivity but would lose nine months of this protection under FDA's current interpretation of the 'transition provisions' for certain protein products that take effect in March 2020.
Insulin Market Competition: Payers Watching FDA 'Transition' Policy
FDA policies around the upcoming regulatory reclassification of insulins as biologics may impact payers' ability to leverage competition and pricing in the market, Express Scripts suggests.
Insulin Market Competition: Payers Watching FDA 'Transition' Policy
FDA policies around the upcoming regulatory reclassification of insulins as biologics may impact payers' ability to leverage competition and pricing in the market, Express Scripts suggests.